Dupilumab Efficacy and Safety in Patients With Persistent Asthma: Asia–Pacific Region
Clinical & Experimental Allergy · 2025-08 · 55 (8) · 691-700
DOI: 10.1111/cea.70005 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical & Experimental Allergy, online erschienen am 23.02.2025. Verfasst von Qingling Zhang und 13 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Dep…. Hauptthemen laut MEDLINE: Asthma, Antibodies, Monoclonal, Humanized, Anti-Asthmatic Agents. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Regeneron Pharmaceuticals, Sanofi.
Abstract (Originalsprache)
Background
Asthma prevalence is increasing in the Asia–Pacific region. China and India account for > 35% of the world's population and are often underrepresented in clinical studies. This phase 3 study (NCT03782532) evaluated efficacy and safety of dupilumab, a monoclonal antibody blocking interleukin‐4/13 signalling, in patients with persistent asthma from China and India.
Methods
Patients (≥ 12 years) were randomised 1:1 to dupilumab 200 mg or matched placebo every 2 weeks for 24 weeks (primary analysis population: blood eosinophils ≥ 150 cells/μL or fractional exhaled nitric oxide ≥ 25 parts per billion without maintenance oral corticosteroid [OCS]; OCS maintenance population: 300 mg OCS). Primary endpoint: change from baseline to week 12 in forced expiratory volume in 1 s (FEV 1 ). Secondary endpoints: change from baseline to week 24 in 5‐item Asthma Control Questionnaire (ACQ‐5/7) scores, annualised severe exacerbation rate, and safety.
Results
In the primary analysis population ( n = 414), change in FEV 1 by week 12 was significantly greater for dupilumab versus placebo (least squares mean difference: 0.31 L [95% CI: 0.23–0.39]; p < 0.0001). At week 24, greater reductions in ACQ‐5 score were seen for dupilumab versus placebo (least squares mean difference: −0.20 [95% CI: −0.35 to −0.05]; p = 0.0097). Dupilumab reduced severe exacerbation risk by 62% versus placebo during the treatment period (relative risk: 0.38 [95% CI: 0.21–0.70]; nominal p = 0.002). Safety was similar between treatment arms; injection‐site reactions were more common with dupilumab treatment (5.0%) than with placebo (1.2%). The OCS maintenance population showed similar outcomes.
Conclusion
Dupilumab significantly improved lung function and asthma control, numerically reduced asthma exacerbations, and was well tolerated in patients from China and India with persistent asthma and evidence of either type 2 inflammation or OCS maintenance. Trial Registration ClinicalTrials.gov identifier: NCT03782532
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Department of Pulmonary and Critical Care Medicine, Guangzhou Institute o…
- Postgraduate Institute of Medical Education and Research, Chandigarh, India.
- The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China.
- Anhui Chest Hospital, Hefei, China.
- The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
- Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
ORCID-Profile: Qingling Zhang
Förderung
- Regeneron Pharmaceuticals
- Sanofi
Zitieren
APA
Zhang, Q., Zhong, N., Dhooria, S., Fu, X., Fang, H., Lin, J., Zhu, S., Laws, E., Wang, Y., Li, V., Hu, C. C., Maloney, J., Abdulai, R. M., & Robinson, L. B. (2025). Dupilumab Efficacy and Safety in Patients With Persistent Asthma: Asia–Pacific Region. Clinical & Experimental Allergy, 55(8), 691-700. https://doi.org/10.1111/cea.70005
Vancouver
Zhang Q, Zhong N, Dhooria S, Fu X, Fang H, Lin J, et al. Dupilumab Efficacy and Safety in Patients With Persistent Asthma: Asia–Pacific Region. Clinical & Experimental Allergy. 2025;55(8):691-700. doi:10.1111/cea.70005
BibTeX
@article{Zhang2025,
author = {Zhang, Qingling and Zhong, Nanshan and Dhooria, Sahajal and Fu, Xiuhua and Fang, Haohui and Lin, Jie and Zhu, Shuyang and Laws, Elizabeth and Wang, Yi and Li, Vivian and Hu, Chih-Chi and Maloney, Jennifer and Abdulai, Raolat M and Robinson, Lacey B},
title = {Dupilumab Efficacy and Safety in Patients With Persistent Asthma: Asia–Pacific Region},
journal = {Clinical & Experimental Allergy},
year = {2025},
volume = {55},
number = {8},
pages = {691--700},
doi = {10.1111/cea.70005}
}
EUVIMED